Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03714620 · ClinicalTrials.gov registry record · Phase 4
Sub-dissociative Dose Ketamine Dosing Study
A Phase 4 study, sponsored by Loyola University.
- Completed
- Registry status
- Phase 4
- Development phase
- 98
- Enrollment target
NCT03714620 is a Phase 4 study that has completed, run by Loyola University. The registered enrollment target is 98 participants.
The verdict
NCT03714620, a Phase 4 study, has completed, sponsored by Loyola University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 98 participants
- Enrollment target
Study Summary
Goal is to determine if in adults presenting to the Emergency Department (ED) with moderate to severe acute pain, Ketamine administered at 0.15 mg/kg will provide similar pain relief to Ketamine administered at 0.3 mg/kg, with fewer adverse effects.
Interventions
- DRUG Ketamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2018-10-15 |
| Est. Completion | 2019-09-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03714620
The ClinicalTrials.gov registry entry for NCT03714620 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loyola University, which has 92 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ketamine is the first listed.
NCT03714620 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03714620 about?
NCT03714620 is a clinical study titled "Sub-dissociative Dose Ketamine Dosing Study". Goal is to determine if in adults presenting to the Emergency Department (ED) with moderate to severe acute pain, Ketamine administered at 0.15 mg/kg will provide similar pain relief to Ketamine administered at 0.3 mg/kg, with fewer adverse effects.
What is the current status of trial NCT03714620?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 98 participants. The study started on 2018-10-15. Estimated completion is 2019-09-17.
What interventions are being tested in trial NCT03714620?
The interventions under investigation include: Ketamine (DRUG).
Who is sponsoring clinical trial NCT03714620?
This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.